Persistent — and at times, politicized — chaos at the FDA is reshaping biotech deal terms and structure, industry sources tell Axios Pro Deals.
Why it matters: Most companies won't have the luxury of waiting to do deals until the agency stabilizes or a new presidential administration takes over.
